In a pivotal development for the pain management sector, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has successfully raised $6 million through a public offering, strengthening its position in the development of novel drug delivery systems. The transaction, which included both common stock and pre-funded warrants at $0.20 per share, attracted significant investor interest in the company’s non-opioid therapeutic pipeline.
Under the guidance of Spartan Capital Securities, LLC as exclusive placement agent, with Lucosky Brookman LLP serving as their legal counsel, the financing provides Virpax with essential capital to advance its strategic objectives. The successful completion of this offering reflects growing market confidence in Virpax’s innovative approach to pain management solutions.